Please try another search
FluoroPharma Medical, Inc., formerly Commercial E-Waste Management Inc., is a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with applications in the area of cardiology. The Company operates through biopharmaceutical research and development segment. It is focused on the development of cardiovascular imaging agents that can detect and assess acute and chronic forms of coronary artery disease (CAD). It has two clinical-stage molecular imaging pharmaceutical product candidates: Flourine-18 (18-F) TPP (BFPET), which includes a ((18F)-labeled cationic lipophilic tetraphenylphosphonium ion (18-F TPP) as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD, and 18-F FCPHA (CardioPET), which includes Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid (18-F FCPHA) as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD.
Name | Age | Since | Title |
---|---|---|---|
Andrew Selwyn | - | - | Member of the Scientific Advisory Board |
Heinrich Schelbert | - | - | Member of the Scientific Advisory Board |
Elazer R. Edelman | 64 | 2007 | Member of the Scientific Advisory Board |
Daniel S. Berman | - | - | Member of the Scientific Advisory Board |
Thomas H. Tulip | 68 | 2015 | CEO, President & Director |
H. William Strauss | - | 2014 | Chair of Scientific Advisory Board |
Peter S. Conti | 65 | 2011 | Member of Scientific Advisory Board |
William Austin Lewis | 45 | - | Independent Director |
Walter Witoshkin | 76 | 2011 | Interim Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review